Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach

Kim, Chang-Gon; Sang, Yun Beom; Lee, Ji Hyun; Chon, Hong Jae

doi:10.3390/ijms22158035

Cited by 39 publications

(25 citation statements)

References 154 publications

(162 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immune checkpoints are increasingly expressed by effector T cells in the tumor microenvironment as cancer progress, resulting in a decreased capacity to kill tumor cells. The phenomenon known as “T cell exhaustion” could be restored by using ICIs, which are now used to treat many types of cancer [ 139 ]. Currently, several monoclonal antibodies were being developed targeting PD-1 (nivolumab, cemiplimab, and pembrolizumab), PD-L1 (atezolizumab, durvalumab, and avelumab), and CTLA-4 (ipilimumab) [ 140 ].…”

Section: Combinatorial Therapy Of Peptide-based Cancer Vaccinesmentioning

confidence: 99%

“…e phenomenon known as "T cell exhaustion" could be restored by using ICIs, which are now used to treat many types of cancer [139]. Currently, several monoclonal antibodies were being developed targeting PD-1 (nivolumab, cemiplimab, and pembrolizumab), PD-L1 (atezolizumab, durvalumab, and avelumab), and CTLA-4 (ipilimumab) [140].…”

Section: Peptide-based Cancer Vaccines and Immune Checkpointmentioning

confidence: 99%

See 1 more Smart Citation

Development of Peptide-Based Vaccines for Cancer

Abd‐Aziz

Poh

2022

Journal of Oncology

View full text Add to dashboard Cite

Peptides cancer vaccines are designed based on the epitope peptides that can elicit humoral and cellular immune responses targeting tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs). In order to develop a clinically safe and more effective vaccine for the future, several issues need to be addressed, and these include the selection of optimal antigen targets, adjuvants, and immunization regimens. Another emerging approach involves the use of personalized peptide-based vaccines based on neoantigens to enhance antitumor response. Rationally designed combinatorial therapy is currently being investigated with chemotherapeutic drugs or immune checkpoint inhibitor therapies to improve the efficacy. This review discusses an overview of the development of peptide-based vaccines, the role of adjuvants, and the delivery systems for peptide vaccines as well as combinatorial therapy as potential anticancer strategies.

show abstract

Section: Combinatorial Therapy Of Peptide-based Cancer Vaccinesmentioning

confidence: 99%

Section: Peptide-based Cancer Vaccines and Immune Checkpointmentioning

confidence: 99%

Development of Peptide-Based Vaccines for Cancer

Abd‐Aziz

Poh

2022

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…The efficacy is limited due to negative regulatory role of various factors in the tumor immunosuppressive environment, including the negative function exerted by the PD-1 axis on vaccine-activated immune cells, resulting in the exhaustion of these cells that are expected to play a role in the eradication of cancer cells. [112][113][114] Therefore, combining PD-1 blockade with therapeutic vaccines may maintain the immune activity of vaccine-activated cells, thus allowing them to efficiently kill tumor cells.…”

Section: With Therapeutic Vaccinesmentioning

confidence: 99%

Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer

Ge¹,

Zhang²,

Zhao³

et al. 2022

DDDT

View full text Add to dashboard Cite

Currently, therapeutic methods for advanced and recurrent cervical cancer patients are limited and unsatisfactory. Immunotherapy is a promising approach for cancer treatment. However, its investigation and application in cervical cancer remain slow. Although pembrolizumab is a remarkable milestone as the first anti-PD-1 mAb approved by the FDA for treating cervical cancer, it shows relatively low response rate. It is noticed that multiple novel immune checkpoints have emerged in recent years, such as CTLA-4, TIGIT, LAG-3, TIM-3, and A2AR. Accumulated studies have suggested that strategies combining the PD-1/PD-L1 inhibitors and different immunotherapies or biotherapies could enhance the antitumor efficacy in human cancers. In this review article, we provide an overview of anti-PD-1/PD-L1-based immunotherapy in cervical cancer treatment. We further summarize the developmental strategies of different immunotherapies or biotherapies combined with PD-1/PD-L1 blockade for treating cervical cancer. We also discuss how these new combined therapies increase the therapeutic benefit gained from experimental evidence in cervical cancer.

show abstract

“…In preclinical studies by Voena et al, an ALK vaccine containing a DNA plasmid coding the intracytoplasmic domain of ALK was shown to be effective in a mouse model of ALK-rearranged NSCLC by inducing a tumor-specific cytotoxic response [ 88 ]. A phase I trial to test this approach in humans is planned [ 89 , 90 ].…”

Section: Current Perspectives and Future Directionsmentioning

confidence: 99%

Vaccine Therapy in Non-Small Cell Lung Cancer

et al. 2022

View full text Add to dashboard Cite

Immunotherapy using immune checkpoint modulators has revolutionized the oncology field, emerging as a new standard of care for multiple indications, including non-small cell lung cancer (NSCLC). However, prognosis for patients with lung cancer is still poor. Although immunotherapy is highly effective in some cases, not all patients experience significant or durable responses, and further strategies are needed to improve outcomes. Therapeutic cancer vaccines are designed to exploit the body’s immune system to activate long-lasting memory against tumor cells that ensure tumor regression, with minimal toxicity. A unique feature of cancer vaccines lies in their complementary approach to boost antitumor immunity that could potentially act synergistically with immune checkpoint inhibitors (ICIs). However, single-line immunization against tumor epitopes with vaccine-based therapeutics has been disappointingly unsuccessful, to date, in lung cancer. The high level of success of several recent vaccines against SARS-CoV-2 has highlighted the evolving advances in science and technology in the vaccines field, raising hope that this strategy can be successfully applied to cancer treatments. In this review, we describe the biology behind the cancer vaccines, and discuss current evidence for the different types of therapeutic cancer vaccines in NSCLC, including their mechanisms of action, current clinical development, and future strategies.

show abstract

Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach

Cited by 39 publications

References 154 publications

Development of Peptide-Based Vaccines for Cancer

Development of Peptide-Based Vaccines for Cancer

Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer

Vaccine Therapy in Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About